Understanding CAR T-Cell Therapy: Guidance for Current Clinic and Future Directions

Join us for this expert-led, live-streamed symposium to get up to date on best practices in the use of CAR T-cell therapy, with a focus on the role of managed care and specialty pharmacy professionals in the care of patients undergoing treatment with CAR T cells.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Agenda

  • Overview of CAR T-cell therapy
  • Best practices and current data with approved CAR T-cell therapies for lymphomas, multiple myeloma, and ALL
    • Patient eligibility
    • Key efficacy and safety data
    • Administration best practices
    • Cost effectiveness data
  • Emerging investigational CAR T-cell therapies
  • Overview of AE management
  • The managed care professional and oncology pharmacist’s role in CAR T-cell therapy
  • Audience Q&A

Events

Date / Time
Event Details

Faculty

Faculty
Craig Freyer, PharmD

Clinical Pharmacy Specialist
Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy
Department of Pharmacy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Faculty
Zahra Mahmoudjafari, PharmD, BCOP, DPLA

Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematological Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Westwood, Kansas

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of managed care and specialty pharmacy professionals and other healthcare professionals to confidently and competently integrate CAR T-cell therapy into their clinical practices.

Target Audience
This educational program is intended for managed care and specialty pharmacy professionals and other healthcare providers who care for patients with hematologic malignancies.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review the biologic principles underlying CAR T-cell therapy, structure and function of the CAR, and the mechanism of action of CAR T-cells
  • Identify characteristics of patients who are candidates appropriate for treatment with CAR T-cell therapy
  • Provide safe and effective patient care services through an understanding of the clinical trial data on CAR T-cell–based therapies used to treat patients with leukemia or B-cell lymphomas, myeloma, or chronic lymphocytic leukemia

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-126-L01-P

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.